The OPADE research project has been highlighted in the Health-NCP-Net 3.0 (HNN 3.0). This network facilitates trans-national co-operation between National Contact Points (NCPs) for Cluster 1 “Health” (CL1) with a view to identifying and sharing good practices and raising the general standard of support to potential applicants of Horizon Europe in the Health Sector.

The article features an interview with the project coordinator, Dr Giulio Corrivetti, highlighting the key objectives and impact of OPADE in the field of health. This recognition underlines the relevance of the project and reinforces its contribution to the advancement of knowledge and innovation in the treatment of depression.

We invite you to visit https://www.healthncp.net/ and read the full article to learn more about how, through the use of personalised medicine, OPADE aims at correlating the omic, genetic and immune profiles of patients suffering from depression to the appropriate antidepressants that will be effective for each patient: https://www.healthncp.net/success-stories.

Biokeralty's role in OPADE focuses on managing the dissemination, communication and exploitation of the results. In addition, Fundación Universitaria Sanitas, the university of the Keralty group, also participates in the project as a clinical site, recruiting patients who undergo clinical evaluation and collecting different biological samples for subsequent analysis.

Stay tuned via our website (https://opade-project.eu/) and our social media channels (https://www.linkedin.com/in/opade-project-828815264/ and https://x.com/OpadeProject/ ). Together, we continue to make a significant impact.